Future Cardia offering is now closed and is no longer accepting investments.
INVEST IN FUTURE CARDIA TODAY!
Voice of the Heart
$3,045,157 Raised
Reasons to Invest
- World-renowned cardiologists, engineers and scientists: with over 180 years of combined expertise in cardiology and medical devices development with multiple exits and one IPO.
- Raised $4M ($3.3m on Republic and $700K from Super Angels) in 2021 to disrupt the $5B Heart Failure monitoring market.
- Stanford StartX: is the premier accelerator program in the world with one of the highest success rates along with 10 startups achieving unicorn status in the past 12 years. StartX companies have a combined valuation of over $30B and 92% survival rate. Over 300 Silicon Valley mentors participate in the program.
- Johnson and Johnson's JLABS: is a global network of open innovation ecosystems, enabling and empowering innovators to accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS companies have a combined valuation of $9.4B. Five IPOs, Eight acquisitions.
OVERVIEW
Cardiologist and Patients Deserve a Better Option
Cardiologists today lack good options for monitoring their heart failure patients at home. Future Cardia is developing an implanted remote cardiac monitor to address this problem. Designed to provide comprehensive data and analysis to doctors, Future Cardia also aims to build the largest collection of long-term cardiac data to improve the lives of patients.
- Detects early signs of Heart Failure problems before symptoms
- Pre-clinical testing with 26 heart failure patients
- Preparing for lab testing and then human implant in 2022 using Electrocardiogram (ECG) and heart sounds with remote monitoring technology to monitor heart
- Provides actionable and quantifiable data analytics for the cardiologists
THE PROBLEM
A lack of remote Heart Failure monitoring solutions makes it difficult for heart failure patients and healthcare providers to address emergencies. As a chronic disease, our patients and physicians are stuck between real emergencies and false alarms, resulting in referral to the Emergency Department and subsequent admission to the hospital, even if it is a false alarm.
Heart failure is a cardiac condition that often results in breathing problems and frequent hospitalizations. Heart Failure patients have weakened heart muscles. As the heart begins to fail, fluid slowly accumulates in the lungs, which can lead to sudden and severe breathing problems.
In the US alone, six million patients suffer from Heart Failure. Canada and Europe are facing the same problem. Because of the lack of a remote monitoring solution for Heart Failure, patients are referred to the ER and subsequently hospitalized, even if it is a false alarm.
Invasive heart procedure devices such as CardioMems by Abbott (acquired for $455 million) are the current standard. This device requires a sensor implant inside the heart or around the heart (Pulmonary Artery) in a cath lab procedure. Accurate, however, they are expensive, complex and are not the ideal solution for all patients.
Wearable monitors are ideal for short-term solutions, however, they suffer from low accuracy, patient non-compliance, and limited data. Therefore, they have a limited use when it comes to long-term Heart Failure monitoring.
THE market
$5 Billion Total Addressable Market Opportunity
Initially, Future Cardia will focus on the one million patients suffering from heart failure, who are in immediate need of remote monitoring solutions. Eventually we hope to reach all six million Americans who suffer from heart failure.
THE solution
A Cardiac Monitor Using Remote Monitoring Technology and AI
Future Cardia is developing a tiny, insertable cardiac device to monitor Heart Failure and reduce unnecessary hospitalizations. The device utilizes multi-sensors, remote monitoring technology and cloud based Artificial Intelligence for long-term comprehensive cardiac monitoring.
This is a simple 2-minute office procedure that does not require a follow up, saving time for both patients and cardiologists. The device is inserted under the skin for improved accuracy, and does not require invasive surgery that other implanted devices do.
By tracking trends in ECG and Heart Sounds readings, physicians can detect heart failure decompensation before the onset of symptoms. This gives them actionable data to steer the patient away from further complications.
Billions of data points for a comprehensive long term cardiac monitoring solution
Future Cardia is developing a compact cardiac device that is inserted subcutaneously (under the skin) in a two-minute office procedure. Once administered, each device yields billions of data points, allowing healthcare providers to compare trending changes over 2-3 years for continuous cardiac monitoring. As Future Cardia collects more data, the analysis will improve through the use of machine learning and AI using ECG and Heart Sounds as biomarker for Cardiology.
Our product relies on three main features: an acoustic sensor, an ECG, and a 3-Axis Accelerometer. The acoustic sensor listens to heart and lung sounds, while the Electrocardiogram (ECG) records heart rhythms and 3-Axis Accelerometer records activity, posture and body orientation.
Our device has high patient compliance over the long-term, because patients do not need to follow a complex process to monitor their cardiac health.
Recorded cardiac data is securely transmitted to a smartphone, then to a cloud-based Artificial Intelligence algorithm for analysis, which the cardiologist can then review and take action.
By analyzing electrical and physiological trends, Future Cardia detects early signs of cardiac decline even before symptoms appear. This allows clinicians to prioritize at-risk patients, implement therapeutic interventions, and prevent hospitalizations.
why invest
Short Regulatory Path with Existing Insurance Coverage of $7,400 / Device for Commercialization
Future Cardia has a simple go-to-market plan. First, we will focus on two highest volume regions, Texas and Florida. We expect Texas and Florida to generate $5.5 million within two years of launch. Each unit will retail for $5,300/unit with an established reimbursement of $7,400 (insurance coverage). With this business model, we project that our first 5K implants will generate $26M in revenue within 4 years.
Second, we will obtain the most comprehensive, long-term cardiac data to date as biomarkers for cardiology. This will allow Future Cardia to venture into predictions for cardiac events, and human longevity study.
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.
THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE [https://www.sec.gov/Archives/edgar/data/1777274/000121390021002171/ea133381-253g1_oraclehealth.htm].
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
(or click)
ABOUT
HEADQUARTERS
2450 Holcombe Blvd suit J
Houston, TX 77021
WEBSITE
View Site
We are Future Cardia (Oracle Health, Inc.) - Bringing you a tiny insertable cardiac monitor for a long-term heart failure monitoring solution to disrupt the $5B market and to set the stage for Connected Implants. Our approach is a simple 2-minute office procedure that brings simplicity, accuracy, high compliance for long-term monitoring, and existing insurance coverage.
TEAM
Jaeson Bang
Founder & CEO
-Extensive background in sales and product development in implantable devices operations.
-Kellogg MBA
Dimitrios Georgakopoulos, PhD
Director of Science
- Held Chief Science Officer position at a NASDAQ company.
- PhD from Johns Hopkins
Dr. Dan Burkhoff, MD PhD
Medical Advisor
- Multiple exits.
- Served at a VP at Heartware, which was acquired by Medtronic for $1.2B.
Dr. Kevin Heist, MD PhD
Medical Advisor
- Cardiologist with his specialty in the field of Electrophysiology to treat Cardiac Arrhythmias.
- Currently practicing at Mass General Hospital in Boston.
Anatoly Yakovlev, PhD
Data Scientist
- Electrical Engineering and PhD from Stanford University.
- Currently working on AI at a top software company in Silicon Valley.
Professor Frits Prinzen, PhD
Scientist
- Architect of commonly used cardiac models and publisher of landmark research.
Dr. Toshi Okabe, MD
Medical Advisor
- Expertise in managing cardiac arrhythmia and cardiac ablations.
Dr. David Kraus, MD
Medical Advisor
- Top clinical trialist in the US.
TERMS
Future Cardia
Overview
PRICE PER SHARE
$2
DEADLINE
Jun 21, 2022
VALUATION
$20M
AMOUNT RAISED
$3,045,157
Breakdown
MIN INVESTMENT
$250
MAX INVESTMENT
$100,000
MIN NUMBER OF SHARES OFFERED
0
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
2,355,221
Maximum Number of Shares Offered subject to adjustment for bonus shares
Company | : | Oracle Health, Inc. |
Corporate Address | : | 2450 Holcombe Blvd suit J, Houston, TX 77021 |
Offering Minimum | : | $0.00 |
Offering Maximum | : | $8,000,000.00 |
Minimum Investment Amount(per investor) | : | $250.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 0 |
Maximum Number of Shares Offered | : | 4,000,000 |
Price per Share | : | $2.00 |
Pre-Money Valuation | : | $20,000,000.00 |
No perks
PRESS
ALL UPDATES
06.20.22
Less than 24 Hours Left
Hello StartEngine Investor Community.
We are getting close to finalizing our offer.
And huge thanks to our investors, we have raised over $2.9M on StartEngine.
If our investors add an additional $250, then we can reach well over $3M.
Your investment is allowing us to be scrappy and fast! Will stay vigilant for our patients, physicians and you the investor!
Please help us finish this offering strong!!
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
06.19.22
Final Hours to Invest
Hello StartEngine Investor Community.
We are getting close to finalizing our offer.
And huge thanks to our investors, we have raised over $2.8M on StartEngine.
If our investors add an additional $250, then we can reach well over $3M.
Your investment is allowing us to be scrappy and fast! Will stay vigilant for our patients, physicians and you the investor!
Please help us finish this offering strong!!
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
06.18.22
48 Hours Remaining - Let's finish strong
Hello StartEngine Investor Community.
We are getting close to finalizing our offer.
And huge thanks to our investors, we have raised over $2.8M on StartEngine.
If our investors add an additional $250, then we can reach well over $3M.
Your investment is allowing us to be scrappy and fast! Will stay vigilant for our patients, physicians and you the investor!
Please help us finish this offering strong!!
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
06.17.22
Final 3 Days Remaining
Hello StartEngine Investor Community.
We are getting close to finalizing our offer to our investors.
And huge thanks to so many of our investors that have invested again. We have raised over $2.7M from investors like you.
If our investors add an additional $250, then we can reach well over $3M.
Please help us finish this offering strong!!
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
06.16.22
US Patent Office and Future Cardia
Dear Investors,
We are making solid progress on our Patent Process.
We are pleased to report that we have now received a Notification from the United States Patent and Trademark Office (USPTO), indicating that our Petition to Convert Application to a Provisional Application has been Granted.
Thank you so much for your support!!
Jae B
06.15.22
Implant Update - Future Cardia
As we reach the final days of offering, I would like to update you on our implant status.
Our engineering team gathered in to build a beautiful device that will be implanted this week.
Our algorithm is working very nicely, as we will test for automatic sensing and detection software.
It will continuously look at the normal rhythm and start to record when it becomes irregular.
Hugely complex and delicate operation, but we are confident we will achieve it this week.
All our activities are possible because of you the investor!!
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
06.14.22
$2.5M in Investment
Dear StartEngine Investors,
Thank you so much for your support!
We have surpassed $2.5 Million in investments from StartEngine investor community.
-NDA signed with a top medical device company
-Lab Implant #2
- Sensing and Detection
-Human implant on schedule
-hired regulatory team in US and EU
Thank you and more to follow!!
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
06.11.22
Artificial Intelligence and Future Cardia
Dear StartEngine Investors,
We have analyzed the cardiac data from our lab testing.
We can see the electrical and mechanical aspects of the heart that is represented by ECG and Heart Sounds.
And then applied Artificial Intelligence to those data.
They are short, but it is a huge step for us to human implant and subsequent data analytics.
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
06.08.22
NDA Signed with a Top Medical Device Company
Dear StartEngine Investor Community,
Today at Heart Rhythm Society, we have signed a Nondisclosure Agreement (NDA) with one of the biggest med tech companies in the world.
This will allow us to discuss and potentially collaborate that will heighten our presence in Cardiac Devices stage.
More to follow.
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
06.06.22
2 Weeks Remaining
Dear StartEngine Investor Community.
Thank you for your investment in us.
We would not be here without your support. We have reached the final 14 days before we close the offering.
Your funding is allowing us to challenge the old guards at our term.
This allows us to be scrappy, aggressive, and agile.
We believe the current corporations have been sitting on a multi-billion dollar industry with little innovation.
We hope to change that and bring value to patients, physicians and you the investors.
Thank you.
Jae B
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
